NASDAQ:GLUE Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis $22.56 -0.22 (-0.97%) Closing price 04:00 PM EasternExtended Trading$22.92 +0.37 (+1.62%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Monte Rosa Therapeutics Stock (NASDAQ:GLUE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GLUE alerts:Sign Up Key Stats Today's Range$22.54▼$23.6550-Day Range$16.37▼$24.5652-Week Range$4.12▼$25.77Volume1.10 million shsAverage Volume1.19 million shsMarket Capitalization$1.91 billionP/E RatioN/ADividend YieldN/APrice Target$34.83Consensus RatingModerate Buy Company Overview Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden. The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience. In immuno-oncology, Monte Rosa applies its platform to better understand tumor microenvironments and to design molecules that modulate immune cell activity. In neuroscience, the company focuses on identifying targets implicated in neurodegenerative and neuroinflammatory disorders. Through this dual therapeutic focus, Monte Rosa seeks to advance candidates from early discovery through lead optimization and into partnerships or further development stages. Monte Rosa operates at the intersection of technology and biology, collaborating with academic institutions and industry partners to validate its discoveries and expand its library of therapeutic assets. The company is led by a team of experienced executives and scientists with backgrounds in genomics, AI, drug development and venture financing. While primarily based in the United States, Monte Rosa’s platform and partnerships enable it to engage with global research networks and to pursue programs with worldwide impact.AI Generated. May Contain Errors. Read More Monte Rosa Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreGLUE MarketRank™: Monte Rosa Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 344th out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialMonte Rosa Therapeutics has a consensus price target of $34.83, representing about 54.4% upside from its current price of $22.56.Amount of Analyst CoverageMonte Rosa Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Monte Rosa Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to decrease in the coming year, from ($1.23) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is -15.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is -15.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 6.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Monte Rosa Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.75% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 13.08, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently decreased by 7.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.21 News SentimentMonte Rosa Therapeutics has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Monte Rosa Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for GLUE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,768,581.00 in company stock.Percentage Held by Insiders6.40% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Monte Rosa Therapeutics' insider trading history. Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLUE Stock News HeadlinesMonte Rosa Therapeutics : GLUEJuly 21, 2026 | 247wallst.comAnalysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX)July 14, 2026 | theglobeandmail.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.July 27 at 1:00 AM | Base Camp Trading (Ad)Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells 6,000 Shares of StockJuly 8, 2026 | insidertrades.comMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comInsider Selling: Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells 5,407 Shares of StockJuly 2, 2026 | insidertrades.comAfter a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?June 29, 2026 | finance.yahoo.comWells Fargo Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)June 26, 2026 | theglobeandmail.comSee More Headlines GLUE Stock Analysis - Frequently Asked Questions How have GLUE shares performed this year? Monte Rosa Therapeutics' stock was trading at $15.68 at the beginning of 2026. Since then, GLUE stock has increased by 43.9% and is now trading at $22.56. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.06. The business earned $4.21 million during the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative trailing twelve-month return on equity of 40.99% and a negative net margin of 302.69%. When did Monte Rosa Therapeutics IPO? Monte Rosa Therapeutics (GLUE) raised $211 million in an IPO on Wednesday, June 23rd 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Monte Rosa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/07/2026Today7/27/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 GLUE's financial health is in the Green zone, according to TradeSmith. GLUE has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLUE CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees90Year Founded2018Price Target and Rating Average Price Target for Monte Rosa Therapeutics$34.83 High Price Target$40.00 Low Price Target$29.00 Potential Upside/Downside+54.4%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.63 million Net Margins-302.69% Pretax Margin-307.04% Return on Equity-40.99% Return on Assets-25.94% Debt Debt-to-Equity RatioN/A Current Ratio9.54 Quick Ratio9.54 Sales & Book Value Annual Sales$123.67 million Price / Sales15.41 Cash FlowN/A Price / Cash FlowN/A Book Value$3.58 per share Price / Book6.30Miscellaneous Outstanding Shares84,480,000Free Float79,072,000Market Cap$1.91 billion OptionableOptionable Beta1.56 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:GLUE) was last updated on 7/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
